EXACT Sciences (NASDAQ:EXAS) and National Research (NASDAQ:NRC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.
This is a summary of recent ratings for EXACT Sciences and National Research, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
EXACT Sciences currently has a consensus price target of $122.93, indicating a potential upside of 32.19%. Given EXACT Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe EXACT Sciences is more favorable than National Research.
Insider and Institutional Ownership
86.6% of EXACT Sciences shares are owned by institutional investors. Comparatively, 39.7% of National Research shares are owned by institutional investors. 2.2% of EXACT Sciences shares are owned by company insiders. Comparatively, 4.5% of National Research shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Risk and Volatility
EXACT Sciences has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500. Comparatively, National Research has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.
Valuation and Earnings
This table compares EXACT Sciences and National Research’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|EXACT Sciences||$454.46 million||26.57||-$175.15 million||($1.36)||-68.38|
|National Research||$119.69 million||13.92||$30.05 million||N/A||N/A|
National Research has lower revenue, but higher earnings than EXACT Sciences.
This table compares EXACT Sciences and National Research’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
EXACT Sciences beats National Research on 7 of the 13 factors compared between the two stocks.
EXACT Sciences Company Profile
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
National Research Company Profile
National Research Corporation (NRC) is a provider of analytics and insights that facilitate revenue growth, patient, employee and customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. The Company’s portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The Company’s clients range from acute care hospitals and post-acute providers, such as home health, long term care and hospice, to numerous payer organizations. The Company derives its revenue from its annually renewable services, which include performance measurement and improvement services, healthcare analytics and governance education services.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.